Communiqués Novo Nordisk A/S

Actions

NOVO B

DK0062498333

Produits pharmaceutiques

Temps réel estimé Cboe Europe Autres places de cotation 16:08:12 12/06/2026			Varia. 5j.	Varia. 1 janv.
285,55 ^DKK	+1,06%		+4,28%	-12,79%

15:15	États-Unis : certains employeurs prévoient de cesser le remboursement des traitements GLP-1 contre l'obésité dès 2027	MT
12:31	PALMARÈS : Virgin Wines abaisse ses prévisions ; Cizzle progresse grâce à un brevet	AN

Communiqués

11/06	Novo Nordisk A/S: IT Security incident at Novo Nordisk	GL
11/06	Novo Nordisk A/S: IT Security incident at Novo Nordisk	AQ
11/06	Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK	GL
11/06	Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK	AQ
11/06	The Secret Behind The Success Of WeGovy - Inside Novo Nordisk (Podcast)	AQ
09/06	Novo Nordisk focuses on longevity and aesthetic medicine, going beyond weight loss	AQ
08/06	Novo Nordisk A/S - share repurchase programme	GL
03/06	Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care	GL
02/06	Parker Waichman LLP Files Lawsuit on behalf of Pennsylvania Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Wegovy	AQ
01/06	Novo Nordisk A/S - share repurchase programme	GL
26/05	Novo Nordisk A/S - share repurchase programme	GL
26/05	Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke	GL
26/05	Novo Nordisk global observational study reveals 2 in 5 people with cardiovascular disease have cardiovascular inflammation, increasing their risk of heart attack and stroke	AQ
25/05	Denmark raises growth forecasts thanks to strong pharmaceutical sector	AQ
22/05	Novo Nordisk A/S: CHMP recommends EU approval of Wegovy® 7.2 mg in a single-dose pen, providing up to 20.7% mean weight loss (1)	GL
22/05	Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class	GL
22/05	Novo Nordisk A/S: Wegovy® pill (oral semaglutide) recommended by CHMP for approval in the EU as the first oral GLP-1 representing the most efficacious oral obesity treatment in its class	AQ
20/05	Trademark Enforcement And Public Interest In Pharmaceutical Disputes: The Delhi High Court’s Approach In Novo Nordisk A/S v. Dr. Reddy’s Laboratories Ltd	AQ
19/05	Novo Nordisk to unveil data showing semaglutide tackles the liver disease crisis affecting about 1 in 3 people living with overweight and obesity worldwide	GL
19/05	BioStock launches Consensus Analysis – a new analytical format for Nordic life science	AQ
18/05	Novo Nordisk A/S - share repurchase programme	GL
15/05	AI In Health Care Is Scaling Quickly—As Regulation Lags, Internal Controls Need To Keep Pace	AQ
13/05	Wegovy® pill delivered 21.6% weight loss in early responders and doubled mobility improvement, according to new Novo Nordisk data at ECO2026	GL
12/05	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
12/05	Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity	GL